Altimmune Q4 Earnings Call Highlights

Altimmune (NASDAQ: ALT) executives used the company's year-end 2025 results call to outline preparations for a pivotal Phase 3 program for pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH), while also providing updates on ongoing Phase 2 studies in alcohol use disorder (AUD) and alcohol-related liver disease (ALD) and reviewing year-end liquidity. Management frames pemvidutide's positioning in liver